Inhibition of lectin-like oxidized low-density lipoprotein-1 receptor protects against plasma-mediated vascular dysfunction associated with pre-eclampsia

American Journal of Hypertension

Volumn 26, Issue 2, 2013, Pages 279-286

  English, Fred A ^a   McCarthy, Fergus P ^a   McSweeney, Catherine L ^a   Quon, Anita L ^b   Morton, Jude S ^b   Sawamura, Tatsuya ^c   Davidge, Sandra T ^b   Kenny, Louise C ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF ALBERTA   (Canada)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

blood pressure; hypertension; LOX 1; oxLDL; pre eclampsia; vascular dysfunction

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; BRADYKININ; LOW DENSITY LIPOPROTEIN; NITROPRUSSIDE SODIUM; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; TS 20; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD VESSEL; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OMENTUM; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADULT; ARTERIES; BRADYKININ; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LIPOPROTEINS, LDL; NITROPRUSSIDE; OMENTUM; OXIDATIVE STRESS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; SCAVENGER RECEPTORS, CLASS E; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 84876561566     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hps035     Document Type: Article

References (39)

1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631-644.
2. Myatt L, Webster RP. Vascular biology of preeclampsia. J Thromb Haemost 2009;7:375-384.
3. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008;294:H541-550. (Pubitemid 351253261)
4. Sankaralingam S, Xu Y, Sawamura T, Davidge ST. Increased lectin-like oxidized low-density lipoprotein receptor-1 expression in the maternal vasculature of women with preeclampsia: role for peroxynitrite. Hypertension 2009;53:270-277.
5. Morton JS, Abdalvand A, Jiang Y, Sawamura T, Uwiera RR, Davidge ST. Lectin-like oxidized low-density lipoprotein 1 receptor in a reduced uteroplacental perfusion pressure rat model of preeclampsia. Hypertension 2012;59:1014-1020.
6. Sankaralingam S, Xu H, Jiang Y, Sawamura T, Davidge ST. Evidence for increased methylglyoxal in the vasculature of women with preeclampsia: role in upregulation of LOX-1 and arginase. Hypertension 2009;54:897-904.
7. Yoshimoto R, Fujita Y, Kakino A, Iwamoto S, Takaya T, Sawamura T. The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther 2011;25:379-391.
8. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002;95:89-100.
9. Hein TW, Liao JC, Kuo L. oxLDL specifically impairs endotheliumdependent, NO-mediated dilation of coronary arterioles. Am J Physiol Heart Circ Physiol 2000;278:H175-183. (Pubitemid 30101869)
10. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-77. (Pubitemid 27130922)
11. Reiss AB, Anwar K, Wirkowski P. Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) in atherogenesis: a brief review. Curr Med Chem 2009;16:2641-2652.
12. Mitra S, Goyal T, Mehta JL. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther 2011;25:419-429.
13. Inoue N, Okamura T, Kokubo Y, Fujita Y, Sato Y, Nakanishi M, Yanagida K, Kakino A, Iwamoto S, Watanabe M, Ogura S, Otsui K, Matsuda H, Uchida K, Yoshimoto R, Sawamura T. LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem 2010;56:550-558.
14. Kume N, Kita T. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in atherogenesis. Trends Cardiovasc Med 2001;11:22-25. (Pubitemid 32544950)
15. Lu J, Mitra S, Wang X, Khaidakov M, Mehta JL. Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxid Redox Sign 2011;15:2301-2333.
16. Mehta JL, Khaidakov M, Hermonat PL, Mitra S, Wang X, Novelli G, Sawamura T. LOX-1: A new target for therapy for cardiovascular diseases. Cardiovasc Drugs Ther 2011;25:495-500.
17. Raijmakers MT, van Tits BJ, Hak-Lemmers HL, Roes EM, Steegers EA, Peters WH. Low plasma levels of oxidized low density lipoprotein in preeclampsia. Acta Obstet Gynecol Scand 2004;83:1173-1177. (Pubitemid 39626194)
18. Hayman R, Warren A, Brockelsby J, Johnson I, Baker P. Plasma from women with pre-eclampsia induces an in vitro alteration in the endothelium-dependent behaviour of myometrial resistance arteries. BJOG 2000;107:108-115. (Pubitemid 30042733)
19. Crocker IP, Kenny LC, Thornton WA, Szabo C, Baker PN. Excessive stimulation of poly(ADP-ribosyl)ation contributes to endothelial dysfunction in pre-eclampsia. Br J Pharmacol 2005;144:772-780. (Pubitemid 40516117)
20. Walsh SK, English FA, Johns EJ, Kenny LC. Plasma-mediated vascular dysfunction in the reduced uterine perfusion pressure model of preeclampsia: a microvascular characterization. Hypertension 2009;54:345-351.
21. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ 2011;342:d1875.
22. Iwamoto S, Fujita Y, Kakino A, Yanagida K, Matsuda H, Yoshimoto R, Sawamura T. An alternative protein standard to measure activity of LOX-1 ligand containing apoB (LAB)-utilization of anti-LOX-1 single-chain antibody fused to apoB fragment. Journal of Atheroscler Thromb 2011;18:818-828.
23. Hayman R, Warren A, Brockelsby J, Johnson I, Baker P. Plasma from women with pre-eclampsia induces an in vitro alteration in the endothelium-dependent behaviour of myometrial resistance arteries. BJOG 2000;107:108-115. (Pubitemid 30042733)
24. Kakutani M, Ueda M, Naruko T, Masaki T, Sawamura T. Accumulation of LOX-1 ligand in plasma and atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits: identification by a novel enzyme immunoassay. Biochem Biophys Res Commun 2001;282:180-185. (Pubitemid 32924362)
25. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-799. (Pubitemid 40311367)
26. George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens 2011;24(9):964-969.
27. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. Jul 2006;195(1):40-49. (Pubitemid 43927490)
28. Kim YJ, Park H, Lee HY, Ahn YM, Ha EH, Suh SH, Pang MG. Paraoxonase gene polymorphism, serum lipid, and oxidized low-density lipoprotein in preeclampsia. Eur J Obstet Gynecol Reproductive Biol 2007;133:47-52. (Pubitemid 46962877)
29. Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL. Preeclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet 1994;343:645-646. (Pubitemid 24087811)
30. Armstrong VW, Wieland E, Diedrich F, Renner A, Rath W, Kreuzer H, Kuhn W, Oellerich M. Serum antibodies to oxidised low-density lipoprotein in pre-eclampsia and coronary heart disease. Lancet 1994;343:1570. (Pubitemid 24180069)
31. Qiu C, Phung TT, Vadachkoria S, Muy-Rivera M, Sanchez SE, Williams MA. Oxidized low-density lipoprotein (oxidized LDL) and the risk of preeclampsia. Physiol Res 2006;55:491-500. (Pubitemid 44611194)
32. Sanchez SE, Williams MA, Muy-Rivera M, Qiu C, Vadachkoria S, Bazul V. A case-control study of oxidized low density lipoproteins and preeclampsia risk. Gynecol Endocrinol 2005;21:193-199. (Pubitemid 41769994)
33. Navarra T, Del Turco S, Berti S, Basta G. The lectin-like oxidized lowdensity lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb 2010;17:317-331.
34. Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, Tanaka M, Ueda A, Kominami G, Kambara H, Kimura T, Kita T. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 2005;112:812-818. (Pubitemid 41170066)
35. Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kominami G, Kita T. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome-comparison with other biomarkers. J Cardiol 2010;56:159-165.
36. Kamezaki F, Yamashita K, Tasaki H, Kume N, Mitsuoka H, Kita T, Adachi T, Otsuji Y. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 correlates with oxidative stress markers in stable coronary artery disease. Int J Cardiol 2009;134:285-287.
37. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, Pastorino AM, Lo Cascio V, Sawamura T. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 2001;276:13750-13755.
38. Eichhorn B, Muller G, Leuner A, Sawamura T, Ravens U, Morawietz H. Impaired vascular function in small resistance arteries of LOX-1 overexpressing mice on high-fat diet. Cardiovascular Res 2009;82: 493-502.
39. Xu X, Gao X, Potter BJ, Cao JM, Zhang C. Anti-LOX-1 rescues endothelial function in coronary arterioles in atherosclerotic ApoE knockout mice. Arterioscler Thromb Vasc Biol 2007;27:871-877. (Pubitemid 46606719)